Universität zu Köln

Yang, Rongxi, Stoecker, Sarah, Schott, Sarah ORCID: 0000-0002-1714-1147, Heil, Joerg ORCID: 0000-0002-4684-9099, Marme, Frederik, Cuk, Katarina, Chen, Bowang, Golatta, Michael ORCID: 0000-0002-2605-0060, Zhou, Yan, Sutter, Christian, Wappenschmidt, Barbara, Schmutzler, Rita, Bugert, Peter, Qu, Bin, Bartram, Claus R., Sohn, Christof, Schneeweiss, Andreas and Burwinkel, Barbara (2017). The association between breast cancer and S100P methylation in peripheral blood by multicenter case- control studies. Carcinogenesis, 38 (3). S. 312 - 321. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2180

Full text not available from this repository.

Abstract

Breast cancer (BC) is the leading cancer in women worldwide. Changes in DNA methylation in peripheral blood could be associated with malignant diseases. Making use of screening results by llumina 27K Methylation Assay, we validated demethylation of five CpG sites of S100P gene in blood cell DNA of BC patients by three independent retrospective studies with subjects from different centers (Validation I: 235 familial BC case and 206 controls, odds ratio per - 1% methylation > 1.03, and P < 6.00 x 10(-8) for all five CpG sites; Validation II: 189 sporadic BC case and 189 controls, odds ratio per - 1% methylation > 1.03, P < 8.0 x 10(- 5) for four CpG sites; Validation III: 156 sporadic BC case and 151 controls, odds ratio per - 1% methylation > 1.03, P < 6.0 x 10(- 4) for four CpG sites). In addition, the blood-based S100P methylation pattern was similar among BC patients with differential clinical characteristics regardless of stage, receptor status and menopause status. The observed BC-associated decreased S100P methylation in blood mainly originates from the leucocytes subpopulations but not B cells. The methylation levels of most S100P CpG sites were inversely correlated with the expression of S100P in leucocytes (P < 1.2 x 10(- 4)) and in tissue (P < 1.1 x 10(- 4)). This study reveals significant association between blood-based decreased S100P methylation and BC, and provides another proof for the application of altered DNA methylation signatures from blood cells as potential markers for the detection of BC, especially for the early stage.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Yang, Rongxi UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoecker, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Schott, Sarah UNSPECIFIED orcid.org/0000-0002-1714-1147 UNSPECIFIED Heil, Joerg UNSPECIFIED orcid.org/0000-0002-4684-9099 UNSPECIFIED Marme, Frederik UNSPECIFIED UNSPECIFIED UNSPECIFIED Cuk, Katarina UNSPECIFIED UNSPECIFIED UNSPECIFIED Chen, Bowang UNSPECIFIED UNSPECIFIED UNSPECIFIED Golatta, Michael UNSPECIFIED orcid.org/0000-0002-2605-0060 UNSPECIFIED Zhou, Yan UNSPECIFIED UNSPECIFIED UNSPECIFIED Sutter, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Wappenschmidt, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmutzler, Rita UNSPECIFIED UNSPECIFIED UNSPECIFIED Bugert, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Qu, Bin UNSPECIFIED UNSPECIFIED UNSPECIFIED Bartram, Claus R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sohn, Christof UNSPECIFIED UNSPECIFIED UNSPECIFIED Schneeweiss, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Burwinkel, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-237622
DOI:	10.1093/carcin/bgx004
Journal or Publication Title:	Carcinogenesis
Volume:	38
Number:	3
Page Range:	S. 312 - 321
Date:	2017
Publisher:	OXFORD UNIV PRESS
Place of Publication:	OXFORD
ISSN:	1460-2180
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DIFFERENTIAL DNA METHYLATION; WIDE METHYLATION; PLASMA DNA; RISK; MARKER; TISSUE; CELLS; CHEMOTHERAPY; BIOMARKER; SURVIVAL Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/23762